 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12...45678910111213141516 |
- Edurant (rilpivirine) / J&J
New P4 trial: A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients. (clinicaltrials.gov) - Nov 27, 2012
P4, N=40, Recruiting, Sponsor: St Stephens Aids Trust
- | Edurant (rilpivirine) / J&J
New P1 trial: A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants (clinicaltrials.gov) - Oct 30, 2012
P1, N=20, Completed, Sponsor: Janssen R&D Ireland
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P4 trial, Adherence: EPEP: Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. (clinicaltrials.gov) - Oct 25, 2012
P4, N=50, Recruiting, Sponsor: Andrew Carr
- |||||||||| Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Oct 15, 2012
P3, N=426, Recruiting, Sponsor: Janssen-Cilag International NV
- | Edurant (rilpivirine) / J&J
Trial completion, Combination therapy: A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants (clinicaltrials.gov) - Oct 11, 2012
P1, N=20, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed
- Vocabria (cabotegravir oral) / ViiV Healthcare
Enrollment change: A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects (clinicaltrials.gov) - Oct 10, 2012
P1, N=28, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed N=56 --> 28
- Edurant (rilpivirine) / J&J
New P4 trial: Darunavir/ritonavir and rilpivirine in therapy-na (EUDRACT) - Oct 7, 2012
P4, N=40, Ongoing, Sponsor: St Stephen's AIDS Trust
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial: A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (clinicaltrials.gov) - Oct 3, 2012
P3, N=0, Active, not recruiting, Sponsor: St Stephens Aids Trust
- Edurant (rilpivirine) / J&J
New P4 trial: A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection (clinicaltrials.gov) - Sep 23, 2012
P4, N=0, Withdrawn, Sponsor: Janssen Pharmaceutica
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial: Efavirenz to Rilpivirine FDC Switch Study (EUDRACT) - Aug 2, 2012
P3, N=40, Ongoing, Sponsor: St Stephen's AIDS Trust
- |||||| Vocabria (cabotegravir oral) / ViiV Healthcare
New P2b trial, Combination therapy: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine (clinicaltrials.gov) - Jul 15, 2012
P2b, N=244, Active, not recruiting, Sponsor: ViiV Healthcare
- | Edurant (rilpivirine) / J&J
Trial completion: A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin (clinicaltrials.gov) - Jun 28, 2012
P1, N=22, Completed, Sponsor: Janssen R&D Ireland
N=56 --> 28 Recruiting --> Completed
- | Edurant (rilpivirine) / J&J
New P1 trial, Combination therapy: A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants (clinicaltrials.gov) - Jun 6, 2012
P1, N=20, Completed, Sponsor: Janssen R&D Ireland
- ||||| Edurant (rilpivirine) / J&J
Enrollment closed, Combination therapy: A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1 (clinicaltrials.gov) - May 28, 2012
P3, N=488, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Edurant (rilpivirine) / J&J
Trial completion, Combination therapy: TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (clinicaltrials.gov) - May 13, 2012
P3, N=680, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J
New P4 trial: Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress (clinicaltrials.gov) - Apr 23, 2012
P4, N=40, Active, not recruiting, Sponsor: Indiana University
- |||| Edurant (rilpivirine) / J&J
Trial completion: A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines (clinicaltrials.gov) - Apr 5, 2012
P2b, N=372, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J
New P1 trial: The Rilpivirine Cerebrospinal-fluid (CSF) Study (clinicaltrials.gov) - Mar 21, 2012
P1, N=15, Recruiting, Sponsor: Imperial College London
- ||||||| Edurant (rilpivirine) / J&J
Trial completion, Combination therapy: TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine. (clinicaltrials.gov) - Mar 19, 2012
P3, N=694, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Trial completion: A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects (clinicaltrials.gov) - Mar 14, 2012
P1, N=28, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Edurant (rilpivirine) / J&J
New P1 trial: A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of Digoxin (clinicaltrials.gov) - Jan 24, 2012
P1, N=22, Completed, Sponsor: Janssen R&D Ireland
- | Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J
Trial completion: TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278 (clinicaltrials.gov) - Dec 11, 2011
P1, N=19, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Intelence (etravirine) / J&J
Trial completion: TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. (clinicaltrials.gov) - Nov 22, 2011
P1, N=33, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Edurant (rilpivirine) / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion: TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir (clinicaltrials.gov) - Nov 22, 2011
P1, N=48, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Vocabria (cabotegravir oral) / ViiV Healthcare
New P1 trial: A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects (clinicaltrials.gov) - Nov 6, 2011
P1, N=28, Completed, Sponsor: ViiV Healthcare